Supplementary Table 4 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates
crossref（2024）
摘要
Supplementary Table 4. Adverse events of any grade that were reported in at least 5% of patients.
查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要